Background. Leprosy, the leading infectious cause of disability worldwide, remains a major public health challenge in the most severely affected countries despite the sharp decline in new cases in recent years. The search for biomarkers is essential to achieve a better understanding of the molecular and cellular mechanisms underlying the disease.
Pentraxin-3 (PTX3) is the prototypic long pentraxin, which was originally identified as a protein induced by primary inflammatory signals, such as tumor necrosis factor alpha (TNF-α) and interleukin 1β (IL-1β) [1, 2] . PTX3 has sequence homology with such pentraxins as C-reactive protein (CRP; PTX1) and the serum amyloid P component (SAP; PTX2), and, unlike CRP and SAP, its synthesis is extrahepatic [3, 4] . Besides its structural similarities with CRP and SAP, PTX3 has different functions and represents a nonredundant factor of humoral innate immunity against microbes [5] . In addition, PTX3 acts as a soluble pattern recognition receptor recognizing both damageand pathogen-associated molecular patterns (DAMPs/PAMPs). It binds to the complement component C1q, the extracellular matrix protein TSG6, and selected pathogens [6] [7] [8] [9] .
PTX3 is stored in neutrophilic-specific granules but can rise quickly after neutrophil degranulation [10] . Even though PTX3 has a short half-life in serum [11] , elevated serum PTX3 levels are sustained by de novo production by endothelial cells, monocytes, macrophages, and dendritic cells in response to activation of Tolllike receptor (TLR) 2, as well as inflammatory stimuli [1, 2, [12] [13] [14] [15] .
Leprosy currently affects millions of people, remaining the leading cause of infectious neuropathy and its consequent disabilities [16] . Erythema nodosum leprosum (ENL), an immunological and inflammatory complication of multibacillary leprosy, affects approximately 50% of patients with multibacillary disease [17, 18] which may lead to the exacerbation of nerve damage and disabilities. ENL is characterized by the occurrence of inflammatory, erythematous nodules (located in apparently normal skin or subcutaneous tissue) often associated with systemic manifestations such as fever, malaise, and neutrophilic leukocytosis [19, 20] . ENL may occur before, during, or after completion of multidrug therapy (MDT), and some patients experience multiple episodes involving a number of organs. The early detection and intervention of this malady is essential to reducing and ultimately preventing disabilities. However, both the molecular mechanisms triggering ENL and those involved in remission remain unclear.
Our hypothesis is that PTX3 may play an important role in the immunopathogenesis of leprosy. Previous studies have indicated PTX3 as a prognostic biomarker in patients with systemic and vascular inflammation [21] [22] [23] .
In the present study, we report evidence that PTX3 is released systemically and at the site of ENL lesions. Additionally, thalidomide treatment of ENL downregulated PTX3 levels, thus reinforcing the role of PTX3 as a potential target during ENL. A more thorough understanding of the pathogenesis of ENL could lead to the development of effective strategies to control its inflammatory process along with novel therapeutic approaches and the identification of biomarkers that might be used as predictive markers as well.
MATERIALS AND METHODS

Study Design and Patient Cohort
This case-control based study was conducted at the Souza Araújo Outpatient Clinic, a reference center for leprosy diagnosis and treatment (Leprosy Laboratory, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil). The study population was divided into 2 groups: (1) health volunteers (n = 25; 15 females and 10 males, ranging in age from 19 to 55 years), and (2) leprosy patients (n = 81; 57 males, 24 females; age range, 10-72 years). All leprosy patients were recruited with approval from the Ethics Committee of the Oswaldo Cruz Foundation. Informed written consent was obtained from all individuals included in the study and from the parents of all participants under the age of 18. Leprosy was diagnosed according to the criteria of Ridley and Jopling [24] . All paucibacillary patients (PB) were classified as borderline tuberculoid, and all multibacillary patients (MB) as borderline lepromatous or lepromatous leprosy. Leprosy was treated with MDT as recommended by the World Health Organization. The case definition of ENL was a diagnosed leprosy patient with an acute appearance of crops of tender cutaneous or subcutaneous lesions, accompanied or not by fever, malaise, or other systemic involvement. The case definition of reversal reaction (RR) referred to those leprosy patients presenting the acute inflammation of preexisting leprosy lesions and/or the onset of new erythematous skin lesions. In addition, healthy volunteers participated as an endemic control group lacking clinical signs or symptoms of leprosy or tuberculosis. The baseline characteristics of each group of individuals enrolled in the study are shown in Table 1 .
ENL Severity Scale
The clinical classification of mild, moderate, and severe ENL was ascertained in accordance with a patient's clinical symptomatology and previously described [25] . See the Supplementary Data for details.
Clinical Samples
In brief, in this study we used biobanked serum samples of untreated leprosy patients without clinical reactions (and before MDT) and newly diagnosed patients with reactions. Sera were collected aseptically, processed under sterile conditions, stored in aliquots, and kept frozen until use (-20°C). Skin biopsy specimens (6 mm in diameter) containing both epidermis and dermis were taken from an active ENL skin lesion at the moment of reactional diagnosis. Ten ENL patients were tracked and a second skin biopsy was taken 7 days after beginning thalidomide treatment at 100 or 300 mg/day. The biopsies were split in half: One portion was fixed in 10% buffered formalin and the other was snap-frozen in liquid nitrogen. Serum samples were used for determination of PTX3 levels by enzyme-linked immunosorbent assay (ELISA). Skin samples were used for histopathological analyses, immunohistochemical staining, and reverse-transcription quantitative polymerase chain reaction (RT-qPCR). All samples were collected from 2009 through 2015.
Histology
The leprosy skin samples were processed and embedded in paraffin and serially sectioned in the sagittal plane at 5 μm thickness on a Leica microtome. Sections were stained with hematoxylin and eosin to study morphology. Slides were viewed through a Nikon Eclipse E400 microscope (Nikon Instruments), and images were acquired by using the INFINITYX-32C camera and Infinity Capture software 6.1.0 (Lumenera Corporation).
Immunohistochemical Staining
Immunohistochemical procedures in skin samples were performed as described previously [25] . Samples were initially blocked with normal horse serum prior to labeling with a monoclonal antibody against PTX3 (Abcam) and appropriate isotype control. Sections were then labeled with biotinylated secondary antibody followed by incubation with avidin-biotin complex (VECTASTAIN Elite ABC Kit Mouse immunoglobulin G [IgG] ). Slides were counterstained with Mayer's hematoxylin and mounted with aqueous Faramount mounting medium. Images were obtained via Nikon Eclipse microscope with Infinity Capture software.
Immunofluorescence Assay
Double immunofluorescence on leprosy skin lesions was performed and examined as described previously [25] . In brief, Abbreviations: BI, bacillary index; EC, endemic controls; ENL, erythema nodosum leprosum; PB, paucibacillary patients without reaction; PB/RR, paucibacillary patients with reversal reaction; MB, multibacillary patients without reaction; MB/RR, multibacillary patients with reversal reaction; MB/ENL, multibacillary patients with erythema nodosum leprosum.
antibodies against PTX3 (Abcam) and myeloperoxidase (MPO; Santa Cruz Biotechnology) and their respective isotypes were incubated with tissue sections followed by incubation with an Alexa Fluor 532 goat antirat IgG and Alexa Fluor 633 goat antirabbit IgG specific secondary antibodies (ThermoFisher Scientific). The nuclei were stained with 40-6-diamidino-2-phenylindole (DAPI, Molecular Probes), and slides were mounted with VECTASHIELD Mounting Medium (Vector Laboratories). Tissues were imaged using an Axio Observer.Z1 fluorescence microscope equipped with a Colibri.2 illumination system (Carl Zeiss) and the EC PlanNeofluar 10×/0.3, 40×/1.30 oil, and 100×/1.30 oil objectives.
Images were acquired with a digital camera AxioCam HRm and AxioVision Rel. 4.6 software (Carl Zeiss). PTX3 and MPO mean fluorescence intensities were quantified using the "Measure" plugin of the ImageJ 1.50 g image analysis software (Wayne Rasband, National Institutes of Health). ImageJ was also used for colocalization analysis, as previously described [26] . A minimum of 10 random images per sample were evaluated for each experiment.
Real Time Polymerase Chain Reaction Quantifications
Total RNA was extracted from skin lesion specimens' using TRIzol (ThermoFisher Scientific), following the manufacturer´s instructions. Complementary DNA was synthesized as described previously [25] . Quantitative PCR was performed using TaqMan-designed primers and probes (ThermoFisher Scientific): PTX3 (Hs00173615_m1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Hs99999905_m1), and TaqMan Fast Universal PCR Master Mix (2X). GAPDH was used as a normalizer in all samples and the expression values obtained were corrected and quantified by converting the cycle threshold value into a numerical value by using the 2 -∆CT method. See the Supplementary Data for details.
Flow Cytometry
Neutrophil CD64 expression was performed using the Leuko64 test kit as specified by the manufacturer (Trillium Diagnostic). Cells were acquired and analyzed as described previously [25, 27] . See the Supplementary Data for details.
ELISA
Measurements of PTX3 were performed on frozen serum samples by commercial ELISA as specified by the manufacturer (R&D Systems). The detection limit of the assays is 218.75 pg/mL. This assay did not cross-react with CRP. For each parameter, values represent the mean of duplicate determinations in each sample.
Statistical Analysis
Statistical analysis was performed with GraphPad Prism version 5 (GraphPad Software). Comparisons between >2 groups of not normally distributed data were examined by way of the Kruskal-Wallis test with Dunn multiple comparison post test. Differences between 2 groups were assessed by the 2-tailed Student t test. The Wilcoxon test was used to compare paired samples. The adopted statistical significance level was P < .05. Spearman correlation coefficient was used to assess association between PTX3 serum levels and polymorphonuclear leukocytes (PMN) CD64 index and tissue expression of PTX3 and MPO. The optimal cutoff values for the PTX3 serum levels were determined from receiver operating characteristic (ROC) curve analysis.
RESULTS
High Concentrations of Circulating PTX3 Are Found in Patients With
Multibacillary Leprosy
PTX3 serum levels (expressed as pg/mL) of MB leprosy patients were about 3.2-fold higher than those among the endemic controls (9155 ± 1507 and 2816 ± 555.2, respectively; P < .001) and were approximately 1.8-fold higher than those of the PB patients (9155 ± 1507 and 4962 ± 1727, respectively; P < .05) ( Figure 1A ). No differences in serum PTX3 were observed between PB patients and endemic controls ( Figure 1A ). The increased PTX3 serum levels in the MB patients suggest that bacillary load could be involved in the release of systemic PTX3. However, no correlation between bacillary index and PTX3 levels was noted among MB patients (r = 0.03406; P = .4635). Our results showed that there was a variation among MB patients, as reflected by the spread of PTX3 serum levels ( Figure 1A ). As reported in Table 2 , mean levels of PTX3 and prevalence were higher in MB patients who experienced ENL reaction later (12 213 ± 2774 and 47.4%). In contrast, MB patients who either progressed to reversal reaction (7146 ± 1426 and 26.3%) or did not evolve to any reactional episode during the 2-6 years after the initial MB leprosy diagnosis (5659 ± 907.6 and 26.3%) presented low levels of PTX3 and prevalence (Table 2) .
We next questioned whether the PTX3 serum levels would be high in leprosy patients at the moment of immunological reaction diagnoses. There was no significant difference in PTX3 serum levels among the MB patients with or without ENL reaction ( Figure 1B) . ENL PTX3 serum levels were about 1.8-fold higher than among those with MB/RR (11 255 ± 1653 vs 6337 ± 1062, respectively; P < .05) and about 2.5-fold higher than the PB/RR patients (11 255 ± 1653 and 4426 ± 1545, respectively; P < .05) ( Figure 1B) . ROC curves were constructed and area under the curve (AUC) analysis highlighted the utility of PTX3 levels for distinguishing between ENL and either MB/RR (AUC = 0.7121; 95% confidence interval [CI], .5378-.9965; P = .04666) or PB/RR (AUC = 0.7963; 95% CI, .6249-.9677]; P = .009708) ( Figure 1C and 1D) . Accordingly with the ROC curve analyses, cutoff points with the best sensitivity and specificity for PTX3 serum levels were 7725 pg/mL for ENL vs MB/RR, and 6674 pg/mL for ENL vs PB/RR.
Thalidomide Treatment Decreases PTX3 Serum Levels in Patients With ENL
To analyze the relevance of PTX3 in the immunopathogenesis of ENL, we investigated the impact of thalidomide treatment on PTX3 serum levels. PTX3 was then assayed in serum samples of ENL patients before and after 7 days of thalidomide treatment (ENL Thal). The median serum PTX3 value during ENL was 1.7-fold higher than what was observed 7 days later with regard to thalidomide (11 461 ± 1456 and 6742 ± 1050, respectively; P < .05) (Figure 2A) . Follow-up analysis of the same ENL patients demonstrated that 10 of the 11 individuals (90.9%) had lower levels of PTX3 after starting thalidomide therapy (P < .01) ( Figure 2B ).
PTX3 Serum Level Is Correlated to Surface Expression of CD64 on Neutrophils
Recently, we demonstrated that circulating neutrophils of ENL patient exclusively expressed CD64 on the cell surface and that thalidomide diminished overall expression [25] . Moreover, the higher levels of CD64 on circulating neutrophils were correlated with disease severity [25] . We then asked whether neutrophil CD64 expression is correlated with PTX3 serum levels. The mean of PMN CD64 index in ENL patients was higher (2.421 ± 0.5798) and was >1.115, the cutoff established in our previous study [25] . The quantitative expression of CD64 showed a significant correlation with the PTX3 serum levels (r = 0.7308; P = .0045).
PTX3 Is Expressed in ENL Lesions, and Thalidomide Treatment Reduces
Its Expression
To ascertain whether PTX3 is involved in the immunopathology of ENL, leprosy patients with acute ENL were followed and skin biopsy specimens were taken at the onset of reactional episode and on the seventh day of thalidomide treatment (n = 10). The clinical features of each patient are summarized in , with reaction (n = 44), with erythema nodosum leprosum (ENL; n = 24), with reversal reaction (RR; n = 11), and paucibacillary with RR (n = 9). Bars show the mean ± standard error in each group. Each symbol represents a patient. Area under the receiver operating characteristic curve (AUC) comparing the PTX3 serum levels for ENL vs multibacillary/RR (C) and ENL vs paucibacillary/RR (D). *P < .05, **P < .01, ***P < .001 (Kruskal-Wallis test).
Supplementary Table 1 . One patient completed MDT 11 years prior to the ENL diagnosis (patient 1). Six patients (patients 2, 4-6, 8, and 9) developed ENL after completing the second year of chemotherapy; 2 patients developed ENL after the sixth and tenth doses of MDT (patient 3 and patient 7, respectively). One newly diagnosed ENL patient who had not received any prior treatment had a reactional episode (patient 10). In this case, MDT was initiated while the patient was undergoing treatment for a reaction due to thalidomide. The lesions of all thalidomide-treated patients greatly improved on day 7 ( Figure 3A and 3C) . Figure 3C shows a typical regressed ENL lesion, represented by flaking skin. Moreover, the inflammatory infiltrate of an ENL skin lesion also regressed after initiating thalidomide ( Figure 3B and 3D) .
Next, the PTX3 gene expression levels at the lesion site were assessed by RT-qPCR and were undetectable in lepromatous leprosy (LL) skin lesions (data not shown). Nevertheless, expression of the PTX3 gene was significantly enhanced in ENL lesions compared to those treated with thalidomide (P < .01) ( Figure 4A ). Immunohistochemical analyses in LL skin lesions indicated that fewer cells within the dermis were positive for PTX3 staining ( Figure 4B ). PTX3-positive staining in ENL lesions was higher within the dermis and was mainly concentrated in the inflammatory infiltrates of untreated ENL patients ( Figure 4C ). Meanwhile, as the result of thalidomide treatment, the staining was substantially reduced ( Figure 4D) .
A major histological hallmark of acute ENL skin lesions is the presence of neutrophils [28] . As neutrophils express MPO, we investigated whether the MPO + cells found in ENL skin lesions corresponded to the areas of PTX3 expression. The majority of MPO + cells presented throughout the ENL lesion colocalized with PTX3 ( Figure 5A and 5D) . Conversely, the dermal PTX3 + cells were greatly diminished in thalidomide-treated ENL lesions ( Figure 5B and 5C ). Furthermore, there was a strong correlation between PTX3 and MPO in these lesions (r = 0.9355; P < .0001). All of the above strongly indicate that neutrophils are an important source of PTX3 in ENL lesions. Thalidomide downmodulates pentraxin-3 (PTX3) serum levels in erythema nodosum leprosum (ENL) patients. A, PTX3 concentration was evaluated by enzymelinked immunosorbent assay in the sera of 12 ENL patients and 9 ENL patients 7 days after starting thalidomide treatment. *P < .05 (Student t test) . B, PTX3 serum concentration of 11 ENL patients at diagnosis (ENL) and 7 days after initiation of thalidomide treatment (ENL Thal). **P < .01 (Wilcoxon test). Bars show the mean ± standard error in each group. Each symbol represents a patient. [ 29, 30] . The rapid liberation of pentraxins at the systemic level or within tissues has been found to correlate with the severity of various clinical conditions. SAP and CRP were elevated in ENL patients [31] [32] [33] . For the first time, the present study was able to quantify PTX3 in leprosy patient serum. We have reported that PTX3 serum levels were high in MB patients without reaction yet persistent in patients who developed ENL reaction. In contrast, MB patients who developed RR had low levels of PTX3 prior to and at the onset of the event. These results indicate that high and persistent levels of PTX3 in MB patients may be associated with the occurrence of ENL, and point to PTX3 as a potential ENL biomarker capable of differentiating from an RR episode. The role of this biological finding is unknown: Is it a simple marker, or does it play a major role in ENL immunopathogenesis? Vascular alterations are frequent in ENL, with vasculitis being the major observable pathological event [34] . PTX3 is considered to be a prognostic biomarker candidate in patients with systemic and vascular inflammation [23, 35] . Currently, no validated ENL biomarker exists. To date, several candidate ENL biomarkers have been identified (eg, CRP, insulin-like growth factor I [IGF-I]) [32, 33, 36] . In a prior report, we pointed to neutrophil CD64 expression as a new ENL biomarker candidate [25] . The higher expression of neutrophil CD64 is positively associated with the severity of clinical symptoms. Correlation analysis showed that the CD64 expression on neutrophils correlates positively with PTX3 serum levels, suggesting that CD64/PTX3 participates in the exacerbation of the inflammatory status of ENL patients. In this connection, the development of a quantitative measure to assess the severity of ENL has been highlighted as a priority research area [37] .
Furthermore, the expression of PTX3 in situ in the ENL lesion was seen. Our data examining ENL lesions corroborate the previously reported association of PTX3 messenger RNA exclusively expressed in ENL lesions [38] . Moreover, our study extends and refines the previous data by showing that PTX3 was indeed downregulated after starting antireactional treatment in correlation with the clinical improvement of ENL patients.
Because PTX3 colocalized with MPO, a specific neutrophilic marker, in ENL lesions, the higher expression of PTX3 could be related to the massive presence of neutrophils. Nonetheless, other sources of PTX3 in ENL lesions cannot be discarded. Human monocyte-derived dendritic cell produces high amounts of PTX3 in response to microbial ligands through engaging different members of the TLR family [12] . It has been reported that lipoarabinomannan produced by Mycobacterium tuberculosis induces expression of PTX3 in human peripheral blood mononuclear cells in vitro [39] . The use of thalidomide is known to reduce systemic symptoms and, as such, is the drug of choice in treating ENL [40, 41] . However, the active mechanisms involved in its performance require further clarification. There is increasing evidence demonstrating the ability of thalidomide to inhibit TNF both in vitro [41] and in vivo [42] , which may play a causal role in the pathogenesis of ENL. Dermal infiltration of neutrophils and T cells in ENL skin lesions was also downregulated by thalidomide in addition to the expression of intercellular adhesion molecule 1 and the major histocompatibility complex class II antigens in the epidermal keratinocytes [25, 41] . Lee et al proposed a novel mechanism of action on the part of thalidomide in the context of ENL [43] . This mechanism would comprise a cascade of events starting with the inhibition of the release of IL-1β, the induction of E-selectin, and subsequent neutrophil binding to endothelial cells. The thalidomide mechanism involved in decreasing PTX3 expression needs to be further examined. At the moment, there is no evidence if PTX3 is targeted by thalidomide, or the ability to decrease TNF influences PTX3 expression. It is possible that PTX3 modulation would be useful for screening of thalidomide analogues.
From a clinical point of view, the availability of a molecule that could identify active ENL and is produced at peripheral inflammatory sites may be useful in identifying leprosy patients who develop active ENL. The main limitation of our study is the number of patients under consideration. Prospective and multicenter studies need to be performed to validate PTX3 as both an ENL biomarker and indicator of the worsening of MB leprosy. and MPO were quantified using ImageJ. Graphs show box plots. Data are presented as mean ± standard error. *P < .05, ***P < .0001 (Wilcoxon test). Scale bars: 20 µm.
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